Leveraging Mobile Technologies in the Development of Novel Digital Endpoints

AbbVie’s Head of Digital Science, Michelle Crouthamel, joins Mobile Technologies in Clinical Trials to discuss how AbbVie has implemented digital health technologies to digitize measurements that can improve existing endpoints, uncover new endpoints and reduce the burden on patients by eliminating the need to travel to sleep labs. Key topics include: Early patient engagement to identify what is meaningful to themHow mobile technologies were implemented into a clinical study and the impactNavigating regulatory acceptance of digital tools for NDE implementation in a clinical trial Speakers: Michelle Crouthamel, Head, Digital Science, AbbvieAntoniu Fantana, PhD, Lead, Emerging Technology Strategy, Clinical Design, Delivery & Analytics, Eli Lilly